Zhang Zhe, Wu Boying, Wang Qijun, Xie Qiaoyi
The Affiliated People's Hospital of Ningbo University, Ningbo City, 315040, Zhejiang, China.
, No. 251, Baizhang East Road, Ningbo City, 315040, Zhejiang, China.
BMC Pulm Med. 2025 Aug 1;25(1):370. doi: 10.1186/s12890-025-03870-z.
The prognosis of children with Mycoplasma pneumoniae pneumonia (MPP) is significantly impacted by the possibility of a missed or delayed diagnosis during the early stages of the illness. In this study, we assessed the potential of utilizing MP antibody and procalcitonin levels as diagnostic markers in pediatric patients with MPP, and their correlation with drug-resistance gene mutations.
A retrospective analysis was conducted on 80 hospitalized children with MPP confirmed by 23 S PCR and 80 healthy controls, focusing on serum MP antibody and procalcitonin (PCT) levels. The diagnostic value was assessed using receiver operating characteristic (ROC) curves. Additionally, PCR combined with TaqMan fluorescent probe technology was utilized to detect drug-resistance gene mutations in the MPP group.
The observation group exhibited significantly higher positive rates of MP antibody and PCT compared to the control group (28.75% vs. 8.75% and 72.50% vs. 18.75%, respectively; P < 0.05). ROC analysis revealed areas under the curve (AUCs) of 0.700 (95% CI: 0.623-0.770) and 0.779 (95% CI: 0.707-0.841) for MP antibody and PCT, respectively, with a combined diagnostic AUC of 0.869 (95% CI: 0.806-0.917) (P < 0.05). Furthermore, 22.5% of children with MPP exhibited drug-resistance gene mutations, associated with increased MP antibody and PCT levels.
MP antibody and PCT levels are promising markers for diagnosing MPP in children, offering enhanced diagnostic value when used in combination. Furthermore, the presence of MP drug resistance gene mutations is associated with increased MP antibody and PCT levels, suggesting that these markers may have potential utility in guiding treatment strategies. Further research is needed to confirm their role in improving patient outcomes.
肺炎支原体肺炎（MPP）患儿的预后在疾病早期因漏诊或延迟诊断的可能性而受到显著影响。在本研究中，我们评估了利用MP抗体和降钙素原水平作为MPP患儿诊断标志物的潜力，以及它们与耐药基因突变的相关性。
对80例经23S PCR确诊的住院MPP患儿和80例健康对照进行回顾性分析，重点关注血清MP抗体和降钙素原（PCT）水平。使用受试者工作特征（ROC）曲线评估诊断价值。此外，采用PCR结合TaqMan荧光探针技术检测MPP组的耐药基因突变。
观察组MP抗体和PCT的阳性率显著高于对照组（分别为28.75%对8.75%和72.50%对18.75%；P<0.05）。ROC分析显示，MP抗体和PCT的曲线下面积（AUC）分别为0.700（95%CI：0.623 - 0.770）和0.779（95%CI：0.707 - 0.841），联合诊断AUC为0.869（95%CI：0.806 - 0.917）（P<0.05）。此外，22.5%的MPP患儿存在耐药基因突变，与MP抗体和PCT水平升高有关。
MP抗体和PCT水平是诊断儿童MPP的有前景的标志物，联合使用时具有更高的诊断价值。此外，MP耐药基因突变与MP抗体和PCT水平升高有关，表明这些标志物可能在指导治疗策略方面具有潜在用途。需要进一步研究来证实它们在改善患者预后中的作用。
